Synbiotic15 – a result of Synbiotic 2000

For many years, our founder Professor Stig Bengmark has researched the role of inflammation and the gut flora when illness occurs. In 1999, Professor Bengmark launched a project together with a couple of research colleagues, in which they collected 535 different lactic bacteria. Their goal was to find an elite among anti-inflammatory bacteria. They studied the bacteria’s ability to produce antioxidants, anti-inflammatory proteins and, in particular, anti-inflammatory cytokines and their ability to induce protective beta-defensin. A special interest was put on the bacteria’s ability to enhance each other’s anti-inflammatory characteristics. 

The result, a composition that was named Synbiotic 2000, which today is only used in research and produced by Super Synbiotics AB Sweden. The composition includes four patented bacteria and 4 grams of selected plant fibres. Synbiotic 2000 was and still is used in research around the world. 

Clinical Studies

Super Synbiotics AB Sweden manufactures compositions for various research projects, including Karolinska Institute in Stockholm and several major research projects around the world. Our synbiotic research composition Synbiotic 2000 is used in studies, on both healthy and sick people, with good results. Time after time Synbiotic 2000 has proven successful in reconditioning the intestinal flora and strengthening the immune system.

The clinical studies indicate a dramatic reduction of life-threatening infections after major abdominal surgeries such as liver transplantations and serious accidents. Treatment with Synbiotic 2000 has resulted in significantly fewer infections, and it reduces complications after surgery. One study indicated that infections after a liver transplant decreased from 51% to 3% when Synbiotic 2000 was used. Another study showed similar results in regards to infections among patients who had been in acute and serious accidents. In this study, the level of infections decreased from over 50% to 14% (Read the full study here).

Live Bacteria

Studies show that the bacterial strains in the composition complement each other. An important aspect when probiotics is given to humans, is that it must be able to survive the move through the gastrointestinal tract, and that it can colonise and stay on the mucous membrane in the intestines for at least a day, but preferably several weeks. Studies on the bacterial strains in Synbiotic 2000 show that they meet this criterion.

Strengthen your gut flora with Synbiotic15

Synbiotic15 is a variant of Synbiotic 2000®. It consists of the same four bacteria (L. Plantarum, L. Paracasei, Pediococcus and Leuconostoc) in a composition with 4 grams of bioactive fibres. These fibres help the 15 billion bacteria to quickly grow and multiply when reaching the gastrointestinal tract. Two of the selected bacterial strains in Synbiotic15, L plantarum and L Paracasei, prove to be key bacteria for the gut flora for people who haven’t adopted well to a Western lifestyle. For many of us, these strains are missing in our gastrointestinal tract and can therefore cause symptoms. This is especially true for those suffering from obesity, and missing these bacteria leads to a significantly higher risk of developing a variety of chronic diseases.

The research

If you would like to know more about the research around our type of products, you can see a selection of our free available papers on the right. We strongly encourage you to search and assess different results on your own. At the end of the day, it’s about how you feel when you use products in our category. What we can say is, that our products undergo rigid quality controls and are used by reputable universities around the world with the aim of creating a healthier lifestyle. If you have any specific questions, you can always get in touch with us via 

Good health starts in the gut

Join our newsletter below to learn everything about gut health and why you want to look after your gut. Every day.

Click on an article below to read more about the research and clinical study